Dosage Forms

Reshaping Dosage Forms

Advancements in personalized medicine and other innovations are transforming the way dosage forms are viewed.

Development of Taste-Masked Oral Dispersible Tablets of Cefpodoxime Proxetil

This study aimed to develop a taste-masked drug resin complex using the ion exchange resin Kyron T-114.

Frontrunners in Bispecific Antibodies

Novel genetic engineering technologies are transforming the design and manufacture of bispecific antibodies, which are emerging as a promising new class of biologics.

USP Publishes Monoclonal Antibody Guidelines

March 02, 2015

A General Chapter on mAbs will be published in USP-NF as biologics increase their role in healthcare.

Considerations for personal protective equipment when handling cytotoxic drugs

March 02, 2015

It is vital that companies involved in the manufacturing and handling of cytotoxic drugs ensure that staff are given the highest possible levels of protection.

FDA Postpones Hearing for Remicade Biosimilar

February 27, 2015

FDA announced that it would postpone a meeting that would be critical for the advancement of Celltrion’s Remicade biosimilar in the US.

Celltrion Launches Remicade Biosimilar in European Markets

February 25, 2015

Remsima will now be available for patients in 12 additional countries in the European Union.

Biological Safety Cabinets Contain Hazardous Drug Powders

February 25, 2015

Enclosures contain powders and particulates during hazardous drug manipulation.

Aprecia Expands Capacity for 3D-Printed Dosage Manufacturing

February 24, 2015

Aprecia Pharmaceuticals' new facility in Ohio will create 150 jobs.

BMS Furthers its Immuno-Oncology Pipeline with Nearly $1.6 Billion in Investments

February 23, 2015

Bristol-Myers Squibb announced that it reached an agreement to acquire Flexus Biosciences and has entered into a $309-million partnership with Rigel Pharmaceuticals.

Celltrion Announces that Remicade Biosimilar Could Save Up to $380 Million USD

February 23, 2015

Celltrion announced that its Remicade biosimilar, Rensima, could save France, Italy, and the UK up to €336 million in costs to treat Crohn’s disease.

Cell Medica Begins Commercial Manufacturing of Cell Therapies

February 19, 2015

The Berlin-Buch facility will begin manufacture of the company’s immune cell therapy.

Single-use Purification Media Improves Efficiency

February 18, 2015

The all-synthetic 3M Emphaze AEX Hybrid Purifier contains both an anion-exchange nonwoven media and a fine-particle, bioburden reduction membrane.